Dupixent

Sanofi and Regeneron's Dupixent scores 3rd FDA approval in sinusitis with nasal polyps
Sanofi and Regeneron's Dupixent scores 3rd FDA approval in sinusitis with nasal polyps
Fierce Pharma
Sanofi
Regeneron
Dupixent
rhinosinusitis
nasal polyps
FDA
Flag link:
FDA Action Alert: Regeneron, Sanofi, Celgene
FDA Action Alert: Regeneron, Sanofi, Celgene
BioSpace
FDA
drug approvals
Acer Therapeutics
Edsivo
Regeneron
Sanofi
Dupixent
Celgene
Revlimid
Alexion
Soliris
Dova Pharmaceuticals
Doptelet
Nabriva Therapeutics
Contepo
Retrophin
Thiola
Flag link:
Rivals’ disappointing results in asthma trial drag down shares of Anaptys Bio
Rivals’ disappointing results in asthma trial drag down shares of Anaptys Bio
Stat
Sanofi
Regeneron
IL-33
asthma
monoclonal antibodies
REGN3500
AnaptysBio
Dupixent
Flag link:
Mark Your Calendar For These June PDUFA Dates
Mark Your Calendar For These June PDUFA Dates
Yahoo/Benzinga
FDA
Merck
Zerbaxa
XERIS
Gvoke HypoPen
Keytruda
Amag Pharmaceuticals
Palatin
Vyleesi
Acer Therapeutics
Edsivo
Sanofi
Regeneron
Dupixent
Alexion
Soliris
Retrophin
Thiola
Allergan
Botox
Flag link:
Go or no go? Merck, Regeneron and Alexion await US expansion
Go or no go? Merck, Regeneron and Alexion await US expansion
EP Vantage
Merck
Keytruda
Sanofi
Regeneron
Dupixent
Alexion
Soliris
FDA
Dova Pharmaceuticals
Retrophin
Flag link:
FDA approves Dupixent for atopic dermatitis in adolescents
FDA approves Dupixent for atopic dermatitis in adolescents
BioCentury
Dupixent
Regeneron
Sanofi
FDA
atopic dermatitis
Flag link:
Sanofi/Regeneron’s Dupixent shows more promise in nasal polyps
Sanofi/Regeneron’s Dupixent shows more promise in nasal polyps
Pharmaforum
Sanofi
Regeneron
Dupixent
clinical trials
nasal polyps
Flag link:
7 drugs that raised eyebrows in Q3
7 drugs that raised eyebrows in Q3
Biopharma Dive
Sanofi
Dupixent
Roche
Herceptin
AbbVie
Humira
Regeneron
Repatha
Clovis Oncology
Rubraca
GSK
Shingrix
Eli Lilly
Trulicity
Flag link:
Going gangbusters in atopic dermatitis, the FDA hands Sanofi and Regeneron a fresh coup for their mega-blockbuster star Dupixent
Going gangbusters in atopic dermatitis, the FDA hands Sanofi and Regeneron a fresh coup for their mega-blockbuster star Dupixent
Endpoints
Sanofi
Regeneron
Dupixent
atopic dermatitis
Flag link:
Sanofi drug Dupixent wins U.S. FDA approval to treat asthma
Sanofi drug Dupixent wins U.S. FDA approval to treat asthma
Yahoo/Reuters
Sanofi
asthma
FDA
Dupixent
Flag link:
Regeneron, Sanofi talks up potential blockbuster franchise as Dupixent sweeps in rhinosinusitis PhIII
Regeneron, Sanofi talks up potential blockbuster franchise as Dupixent sweeps in rhinosinusitis PhIII
Endpoints
Regeneron
Sanofi
Dupixent
nasal polyps
rhinosinusitis
Flag link:
Sanofi unveils eczema drug data, as regulators mull label expansion
Sanofi unveils eczema drug data, as regulators mull label expansion
Pharmaforum
Sanofi
Dupixent
dupilumab
eczema
atopic dermatitis
Flag link:
Regeneron, Sanofi show restraint on Dupixent price hike, but Pfizer’s hard charge continues to spur calls for a radical change-up
Regeneron, Sanofi show restraint on Dupixent price hike, but Pfizer’s hard charge continues to spur calls for a radical change-up
Endpoints
Regeneron
Sanofi
Dupixent
drug pricing
Flag link:
Sanofi's Dupixent scores NICE recommendation after price cut
Sanofi's Dupixent scores NICE recommendation after price cut
Fierce Pharma
Sanofi
NICE
atopic dermatitis
Dupixent
Flag link:
3 Reasons Regeneron Stock Could Start Climbing Again
3 Reasons Regeneron Stock Could Start Climbing Again
Yahoo/Motley Fool
Sanofi
Regeneron
Praluent
Dupixent
Eylea
Flag link:
Sanofi blockbuster-to-be skin drug Dupixent fails to win gatekeeper's backing
Sanofi blockbuster-to-be skin drug Dupixent fails to win gatekeeper's backing
Fierce Pharma
Sanofi
Dupixent
NICE
Flag link:
Sanofi and Regeneron's Dupixent launch is about to get a cash infusion
Sanofi and Regeneron's Dupixent launch is about to get a cash infusion
Fierce Pharma
Sanofi
Regeneron
Dupixent
drug launches
eczema
JPMHC 2018
Flag link:
Regeneron-Sanofi food allergy drug succeeds mid-stage study
Regeneron-Sanofi food allergy drug succeeds mid-stage study
Yahoo/Reuters
Regeneron
Amgen
food allergies
eosinophilic esophagitis
Dupixent
Flag link:
Sanofi and Regeneron, seeking to shield Dupixent, lose first IPR try against Amgen
Sanofi and Regeneron, seeking to shield Dupixent, lose first IPR try against Amgen
Fierce Pharma
Sanofi
Regeneron
Dupixent
IPR
Amgen
patents
Flag link:
Sanofi indicates dupilumab could be used to treat nasal polyps
Sanofi indicates dupilumab could be used to treat nasal polyps
Yahoo/Reuters
Sanofi
dupilumab
Dupixent
nasal polyps
Flag link:

Pages